Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in 1L CLL - 5yr Follow up, Retreatment, and MRD Kinetics

By 2024 ASH Annual Meeting Insights Hub FEATURING Jake Soumerai

59 views

December 20, 2024

Comments 0

Videos

New

Overcoming Clinical Barriers: Integrating Liposomal Irinotecan Into …

Massachusetts General Hospital Cancer Center

P. Pathak

New

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

59 views

New

ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results Fr…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

30 views

New

ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AM…

2024 ASH Annual Meeting Insights Hub

A. Fathi

24 views

New

Proton-Based Radiation Therapy for Chordomas

Massachusetts General Hospital Cancer Center

F. Giap

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia:…

Massachusetts General Hospital Cancer Center

H. Al-Samkari

54 views

Understanding ESR1 Mutations in HR+/HER2- mBC: Testing Methods, Pati…

Massachusetts General Hospital Cancer Center

S. Wander

319 views

Uveal Melanoma for Community Oncologists

Massachusetts General Hospital Cancer Center

K. Montazeri

114 views

2023 SMR Congress Insights: "Time-to-Event Machine Learning Predicti…

Insights from 2023 Society for Melanoma Research Annual Meeting

Y. Semenov

60 views

SOHO 2023: CAR/BsAb Toxicity in MM - Prevention, Treatment, and Surv…

SOHO 2023 Eleventh Annual Meeting

N. S. Raje

161 views

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Insights from 2023 EHA® Annual Meeting

A. Fathi

242 views

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial and S…

Insights from 2023 ASCO® Annual Meeting

J. Lin

86 views

ESR1 Mutations in HR+/HER2- mBC and Their Role in Treatment Outcomes

Massachusetts General Hospital Cancer Center

S. Wander

251 views

Genetic Heterogeneity in Brain Metastases and Implications for Clini…

Massachusetts General Hospital Cancer Center

P. Brastianos

15 views

Maintenance Therapy in AML: Protecting Remission, Extending Survival…

Massachusetts General Hospital Cancer Center

A. Brunner

219 views

ESMO 2021 Updates on 1L DKN-01 + Tislelizumab & Chemotherapy in Adva…

Massachusetts General Hospital Cancer Center

S. Klempner

110 views

Selpercatinib Efficacy & Safety in Patients With RET-Altered Thyroid…

Massachusetts General Hospital Cancer Center

L. Wirth

43 views

Next Steps in FGFRi in Cholangiocarcinoma: FGFR Pathway & Current La…

Massachusetts General Hospital Cancer Center

L. Goyal

238 views

ASCO 2021 Highlights From GEOMETRY mono-1 Study on Advanced NSCLC: C…

Massachusetts General Hospital Cancer Center

R. Heist

40 views

2021 Updates on mTNBC: Do Olaparib/Talazoparib Improve PFS Compared …

Virtual West Oncology Conference

N. Vidula

72 views

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

GRACE

Z. Piotrowska

104 views

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

GRACE

Z. Piotrowska

114 views

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the P…

Massachusetts General Hospital Cancer Center

K. Flaherty

18 views

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dx…

2020 ASCO Virtual Direct™ Highlights

I. Dagogo-Jack

327 views

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

2020 Virtual ESMO Review

I. Dagogo-Jack

29 views

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

2020 Virtual ESMO Review

I. Dagogo-Jack

177 views

2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Ben…

ecancer

A. Bardia

273 views

Risk Factors in Lung Cancer: Which Risk Factor Is Predominant? How I…

Virtual Diversity in Cancer Care

I. Dagogo-Jack

157 views

Login

Login

Join VuMedi